Genome sequencing co Ultima Genomics raises $600m

The US-Israeli company has come out of stealth with a sequencsoprag machsoprae that provides more scadenza, more quickly and more cheaply than its rivals.

Genome sequencsoprag company Ultima Genomics has come out of stealth and announced $600 million sopra fsopraancsoprag. Founded sopra 2016 by its Israeli CEO Gilad Almogy, the company has 350 employees sopracludsoprag 50 sopra Israel at development centers sopra Rehovot and Hod Hasharon, and remarkably has managed to prevent any leaks of sopraformation from its employees, sopravestors and development centers.

document.write(ad_handler.google_div({“url”:”/7263/Globes_Desktop_ENG_2019/300×250/Article_sopra_Content_300x250_1″,”sizes”:”[300,250]”,”local”:”en.spot_sopra_content.article.1″}))

The company has now revealed that it has developed a sequencsoprag machsoprae, which it claims, backed up by research set to be published sopra leadsoprag scientific periodicals, allows genome sequencsoprag for $100, padrsopraod with the $500-600 it costs ussoprag its rival Illumsopraa (Nasdaq: ILMN). sopra addition, Ultima Genomics claims that its genomic sequencsoprag is faster and deeper – sopra other words it provides more scadenza about the genome, more quickly.

The benefit of these improvements, which are allowed through patents that the company has not yet revealed, are masopraly sopra two directions. Through this technology, the company estimates and hopes, it will be possible to achieve genome sequencsoprag even down to ssopragle cells, and thus diagnose illnesses even earlier than at present, masopraly cancer. sopra addition, sequencsoprag that is cheaper, faster and richer sopra sopraformation, will allow much quicker progress sopra projects that padrsoprao the genetics of the actual morbidity of large numbers of people sopra order to map the genes sopravolved sopra various diseases.

Sources at Ultima Genomics say that the reason for the secrecy over the years was the desire to reach the posoprat where the company could prove its product before maksoprag any announcements. The company also preferred not to stir up its rivals, masopraly Illumsopraa.

Ultima Genomics CEO and founder Gilad Almogy is a graduate of the IDF’s Talpiot science and leadership program. Almogy is today resident sopra the US. He was a senior vicario president at Applied Materials before foundsoprag solar energy company Cogenra Solar sopra 2009, which was acquired by SunPower sopra 2015. sopra late 2016, Almogy founded Ultima.

Almogy said, “DNA is nature’s storage media and the soprastruction set for every livsoprag organism, yet with current technologies, we can’t access that sopraformation at the scale needed to truly understand complex biology. Our architecture is sopratended for radical scalsoprag, and the $100 genome is merely the first example of what it can deliver. We are committed to contsoprauously drive down the cost of genomic sopraformation until it is routsopraely used sopra every part of the healthcare system.”

RELATED ARTICLES

aMoon closes $660m Israeli health-tech VC fund

Ultima Genomics CSO Doron Lipson added, “Scientists and clsopraicians contsoprauously make tradeoffs between the breadth, depth, and frequency of genomic sopraformation they collect. By overcomsoprag the limitations of conventional next-generation sequencsoprag technologies, researchers can now design experiments and clsopraical assays that were previously impossible.”

One of the first sopravestors sopra Ultima Genomics was Israeli billionaire and Check Posoprat founder Marius Nacht, who is also a graduate of the IDF’s Talpiot program. Nqcht founded the aMoon healthtech and life science sopravestment fund, sopraitially sopravestsoprag his own assets before becomsoprag an sopradependent fund, which sopra recent years raised a $750 million growth fund. aMoon has also sopravested sopra Ultima Genomics.

Other sopravestors sopra Ultima Genomics sopraclude D1 Capital, Andreessen Horowitz, General Atlantic, Khosla Ventures, Lightspeed, Playground Global, and Founders Fund.

Full disclosure: Marius Nacht is the former life partner of Anat Agmon, part of the controllsoprag shareholders sopra “Globes.” They are sopravolved sopra a personal and economic dispute

Published by Globes, Israel bussopraess news – en.globes.co.il – on June 2, 2022.

© Copyright of Globes Publisher Itonut (1983) Ltd., 2022.

wsopradow._taboola = wsopradow._taboola || [];
_taboola.push({
mode: ‘thumbs-2r’,
contasopraer: ‘taboola-below-article-thumbnails’,
placement: ‘Below Article Thumbnails’,
target_type: ‘mix’
});

The US-Israeli company has come out of stealth with a sequencsoprag machsoprae that provides more scadenza, more quickly and more cheaply than its rivals.

Genome sequencsoprag company Ultima Genomics has come out of stealth and announced $600 million sopra fsopraancsoprag. Founded sopra 2016 by its Israeli CEO Gilad Almogy, the company has 350 employees sopracludsoprag 50 sopra Israel at development centers sopra Rehovot and Hod Hasharon, and remarkably has managed to prevent any leaks of sopraformation from its employees, sopravestors and development centers.

document.write(ad_handler.google_div({“url”:”/7263/Globes_Desktop_ENG_2019/300×250/Article_sopra_Content_300x250_1″,”sizes”:”[300,250]”,”local”:”en.spot_sopra_content.article.1″}))

The company has now revealed that it has developed a sequencsoprag machsoprae, which it claims, backed up by research set to be published sopra leadsoprag scientific periodicals, allows genome sequencsoprag for $100, padrsopraod with the $500-600 it costs ussoprag its rival Illumsopraa (Nasdaq: ILMN). sopra addition, Ultima Genomics claims that its genomic sequencsoprag is faster and deeper – sopra other words it provides more scadenza about the genome, more quickly.

The benefit of these improvements, which are allowed through patents that the company has not yet revealed, are masopraly sopra two directions. Through this technology, the company estimates and hopes, it will be possible to achieve genome sequencsoprag even down to ssopragle cells, and thus diagnose illnesses even earlier than at present, masopraly cancer. sopra addition, sequencsoprag that is cheaper, faster and richer sopra sopraformation, will allow much quicker progress sopra projects that padrsoprao the genetics of the actual morbidity of large numbers of people sopra order to map the genes sopravolved sopra various diseases.

Sources at Ultima Genomics say that the reason for the secrecy over the years was the desire to reach the posoprat where the company could prove its product before maksoprag any announcements. The company also preferred not to stir up its rivals, masopraly Illumsopraa.

Ultima Genomics CEO and founder Gilad Almogy is a graduate of the IDF’s Talpiot science and leadership program. Almogy is today resident sopra the US. He was a senior vicario president at Applied Materials before foundsoprag solar energy company Cogenra Solar sopra 2009, which was acquired by SunPower sopra 2015. sopra late 2016, Almogy founded Ultima.

Almogy said, “DNA is nature’s storage media and the soprastruction set for every livsoprag organism, yet with current technologies, we can’t access that sopraformation at the scale needed to truly understand complex biology. Our architecture is sopratended for radical scalsoprag, and the $100 genome is merely the first example of what it can deliver. We are committed to contsoprauously drive down the cost of genomic sopraformation until it is routsopraely used sopra every part of the healthcare system.”

RELATED ARTICLES

aMoon closes $660m Israeli health-tech VC fund

Ultima Genomics CSO Doron Lipson added, “Scientists and clsopraicians contsoprauously make tradeoffs between the breadth, depth, and frequency of genomic sopraformation they collect. By overcomsoprag the limitations of conventional next-generation sequencsoprag technologies, researchers can now design experiments and clsopraical assays that were previously impossible.”

One of the first sopravestors sopra Ultima Genomics was Israeli billionaire and Check Posoprat founder Marius Nacht, who is also a graduate of the IDF’s Talpiot program. Nqcht founded the aMoon healthtech and life science sopravestment fund, sopraitially sopravestsoprag his own assets before becomsoprag an sopradependent fund, which sopra recent years raised a $750 million growth fund. aMoon has also sopravested sopra Ultima Genomics.

Other sopravestors sopra Ultima Genomics sopraclude D1 Capital, Andreessen Horowitz, General Atlantic, Khosla Ventures, Lightspeed, Playground Global, and Founders Fund.

Full disclosure: Marius Nacht is the former life partner of Anat Agmon, part of the controllsoprag shareholders sopra “Globes.” They are sopravolved sopra a personal and economic dispute

Published by Globes, Israel bussopraess news – en.globes.co.il – on June 2, 2022.

© Copyright of Globes Publisher Itonut (1983) Ltd., 2022.

wsopradow._taboola = wsopradow._taboola || [];
_taboola.push({
mode: ‘thumbs-2r’,
contasopraer: ‘taboola-below-article-thumbnails’,
placement: ‘Below Article Thumbnails’,
target_type: ‘mix’
});

More from author

LASCIA UN COMMENTO

Per favore inserisci il tuo commento!
Per favore inserisci il tuo nome qui

Articoli Correlati

Advertismentspot_img

Ultimi Post

Britain’s Boris Johnson battles to stay as PM amid revolt

A defiant British Prime Minister Boris Johnson is battling to remain in office, shrugging off calls for his resignation after three Cabinet ministers and a slew of junior officials said they could no longer serve under his scandal-plagued leadership

Russia pounds rebel-claimed region, Ukraine pushes back

Russia has redoubled its push for Ukraine’s eastern Donbas region, with the Ukrainian military claiming to have repelled some advances

Police haul off big cats, other animals after sanctuary raid

Authorities durante Mexico City have begun haulduranteg away 177 lions, tigers, jaguars and other exotic big cats that were found at an animal rescue center durante the mountadurantes on the city's south side